Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension

Pulmonary Circulation

Volumn 4, Issue 3, 2014, Pages 456-461

  Preston, Ioana R ^a   Feldman, Jeremy ^b   White, James ^c   Franco, Veronica ^d   Ishizawar, David ^e   Burger, Charles ^f   Waxman, Aaron B ^g   Hill, Nicholas S ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Goal oriented therapy; Multicenter study; Prostacyclin analogues

Indexed keywords

EID: 85026337196     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/677360     Document Type: Article

References (10)

1. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-172.
2. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012;126:349-356.
3. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010;35:1079-1087.
4. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-1263.
5. Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 2007;132: 757-763.
6. Vachiery JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from i.v. epoprostenol to subcutaneous tre-prostinil in pulmonary arterial hypertension. Chest 2002;121: 1561-1565.
7. Steiner MK, Preston IR, Klinger JR, et al. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest 2006;130:1471-1480.
8. de Jesus Perez VA, Rosenzweig E, Rubin LJ, et al. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol 2012;110:1546-1550.
9. McSwain CS, Benza R, Shapiro S, et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J Clin Pharmacol 2008;48: 19-25.
10. Raina A, Coons JC, Kanwar M, Murali S, Sokos G, Benza RL. Transitioning from parenteral treprostinil to inhaled tre-prostinil in patients with pulmonary arterial hypertension. Pulm Circ 2013;3:116-120.